The American Society of Hematology will recognize exemplary hematologists who have made significant contributions to the field with several honorific awards at the 2024 ASH Annual Meeting and Exposition in San Diego on December 7-10.
Fred Hutch Cancer Center announced the recipients of the 2024 Dr. Eddie Méndez Scholar Award, which recognizes early-career scientists from underrepresented backgrounds who are studying cancer, infectious diseases, and basic sciences.
The National Comprehensive Cancer Network announced recognitions for the award-winning library of NCCN Guidelines for Patients and NCCN Patient Webinars.
The Institute for Data Science in Oncology at MD Anderson Cancer Center has established an internal advisory council to identify needs and opportunities for data science development and integration across MD Anderson, advancing work that will yield significant benefits for patients and families.
The Wistar Institute received a $10 million donation from an anonymous donor who previously committed $20 million to support Wistar’s new Center for Advanced Therapeutics.
Michigan State University’s School of Social Work has received $1,125,417 to co-lead a study aimed at improving psychosocial support for mesothelioma caregivers.
Cancer survivors who identify as lesbian, gay, bisexual, transgender, queer, or anything other than straight and cisgender experience more chronic health conditions, disabilities, and other physical and cognitive limitations than non-LGBTQ+ cancer survivors; however, the prevalence of most conditions was highest among transgender or gender non-conforming individuals, according to a study published in Cancer Epidemiology, Biomarkers & Prevention.
The American Society for Radiation Oncology published an updated clinical guideline in Practical Radiation Oncology that details best practices for using radiation therapy to treat patients who have oropharyngeal squamous cell carcinoma caused by the human papilloma virus.
In the phase III STARGLO study of Columvi (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) versus Rituxan (rituximab) in combination with GemOx (R-GemOx) for people with relapsed or refractory diffuse large B-cell lymphoma who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy, the Columvi regiment extended overall survival.
The phase II MagnetisMM-3 study of Elrexfio (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial.
